Skip to content

YVOMEDICAL

Active Private limited companyfounded 2020active for 6 yearsAntoine Depagelaan 9, 1000 BrusselsKBO/BCE: BE 0747.944.036

Lifetime

5 annual accounts with figures on one time axis
peak of €577,924 in 2023
€362,152▼ 3.3%
lowest -€338,466 in 2022
€143,242▼ 5.6%
peak of €199,253 in 2025
€199,253▲ 256%
€373,476▼ 32.6%
Board1 name since 2020
1 director
Documentsfilings and deeds
24-08-202624 days late
2025micro format
(statutory director) and (statutory director) appointed 30-06Equity from €56,011 to €199,253Debts from €553,860 to €373,476

Key points

from the 2025 annual accounts

Equity

€199,253 ▲ 256%
€56,0002024€199,0002025

Equity rose in 2025 from €56,011 to €199,253.

Turnover

≈ €550,000 estimated

The micro format states no turnover.

Filings

5 annual accounts 5 late
AprilJune31 JulyOctober20222024

The 2023 accounts came in latest, 67 days after the end of the period.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 26,972 companies had the same profile as YVOMEDICAL has now. Each dot stands for 68 companies, two years later.

94.9%
were still trading
3.5%
stopped another way
1.6%
went bankrupt
  • Micro
  • 5 to 10 years old
  • solvency 30% or more
  • a profit of 5% of the balance sheet or more
Test of the method

The method was tested on the 497,894 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.7% would go bankrupt within 24 months. In fact 1.8% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.4% 0.5%
3 0.6% 0.6%
4 0.7% 0.8%
5 0.9% 1.0%
6 1.4% 1.6%
7 1.7% 1.8%
8 1.9% 2.0%
9 3.1% 3.3%
10 5.9% 6.4%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 26,972 companies, not a prediction for YVOMEDICAL. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director, since 08-06-2020
  • 100 sharesdeed of 10-06-2020
Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0747944036
(statutory director) and (statutory director) appointed General meeting of 16-05-2025 · Gazette deed
Annee Comptable is in office as director · General meeting of 14-12-2020 · Gazette deed
Incorporation Founding capital of €12,000, 100 shares · Founded by · appointed as director · published on 10-06-2020 · Gazette deed
All 14 events

Comparable companies

same main activity, similar in size and age
Company
YVOMEDICAL Brussels €572,729 €362,152 34.8% -
Dokter Jasmien Dam Oogarts Schilde €564,578 €356,727 47.7% -
DR. VANDUYNHOVEN PHILIPPE Ghent €608,634 €358,097 1.0% -
DR. BERT DU PONT Hasselt €544,888 €350,733 47.1% -
Dr. Abi-Khalil Jâd Beersel €592,360 €392,685 14.6% -
OPHTALMOCARE Waterloo €594,643 €340,551 41.5% -
REUMAPRAKTIJK ZUID-LIMBURG Tongeren-Borgloon €589,217 €392,605 0.8% -

These companies have the same main activity as YVOMEDICAL: specialist medical practice (NACE 86220). They are comparable in size and age: total assets between €545,000 and €609,000, founded between 2019 and 2020.

Official details

Source: KBO
Status
Active since 08-06-2020Normal situation
Activity
Specialist medical practiceNACE 86220
Joint committee
330Health institutions and services · annual accounts 2025
Establishment unit
2.304.365.6521000 Brussels, since 08-06-2020
Financial year end
31 December
Peppol
Reachable since 03-01-2026
Company details

Annual accounts 2025

€572,729▼ 6.1%
Filing
Filed on 24-08-2026
Financials

Insights on YVOMEDICAL

YVOMEDICAL files the micro format. That format states no turnover. The gross margin fell from €423,611 in 2021 to €362,152 in 2025.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about YVOMEDICAL

What is the company number of YVOMEDICAL?
The company number of YVOMEDICAL is 0747.944.036. The VAT number is the same number with BE in front: BE 0747.944.036.
Where is YVOMEDICAL based?
The registered office is at Antoine Depagelaan 9, 1000 Brussels.Company details
What does YVOMEDICAL do?
According to the KBO register, the main activity is specialist medical practice (NACE 86220).
What is the legal form of YVOMEDICAL?
YVOMEDICAL is a private limited company (BV).
When was YVOMEDICAL founded?
YVOMEDICAL was founded on 08-06-2020.
Is YVOMEDICAL still active?
Yes, YVOMEDICAL is an active enterprise in the KBO register.
How many employees does YVOMEDICAL have?
YVOMEDICAL had an average of 1 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
Which joint committee does YVOMEDICAL fall under?
In its 2025 annual accounts, YVOMEDICAL states joint committee 330 (Health institutions and services).
What is the turnover of YVOMEDICAL?
The turnover in financial year 2025 is about €550,000. This figure is estimated from the gross margin of €362,152 and 31 comparable companies (NACE 86220). It probably lies between €480,000 and €760,000.
Is YVOMEDICAL profitable?
In financial year 2025, YVOMEDICAL made a profit of €143,242.
Where can I find the annual accounts of YVOMEDICAL?
YVOMEDICAL filed 5 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of YVOMEDICAL due?
YVOMEDICAL must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.